Stifel Nicolaus Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)

Key Points

• Stifel Nicolaus has initiated coverage on **Tandem Diabetes Care** with a "hold" rating and a price target of **$15.00**, indicating a potential downside of **3.47%** from its current price.
• Recent analyst ratings show a mix, with **four "Buy"**, **twelve "Hold"**, and **one "Sell"**, while the average target price across analysts stands at **$21.19**.
• CEO John F. Sheridan and CFO Leigh Vosseller have both made significant insider stock purchases, indicating confidence in the company's future prospects.

Stifel Nicolaus started coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) in a report released on Tuesday. The firm set a "hold" rating and a $15.00 price target on the medical device company's stock. Stifel Nicolaus' price target would indicate a potential downside of 3.47% from the company's current price.

TNDM has been the topic of several other reports. Wall Street Zen raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Saturday. Lake Street Capital downgraded shares of Tandem Diabetes Care from a "buy" rating to a "hold" rating and reduced their price target for the stock from $75.00 to $12.00 in a research report on Monday, August 11th. Citigroup reaffirmed a "neutral" rating and set a $15.00 price objective (up previously from $11.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 7th. Wells Fargo & Company reduced their target price on shares of Tandem Diabetes Care from $20.00 to $13.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Finally, Piper Sandler lowered shares of Tandem Diabetes Care from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $30.00 to $14.00 in a report on Thursday, August 7th. Four analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $21.19.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $15.54 on Tuesday. The stock has a market cap of $1.05 billion, a P/E ratio of -5.03 and a beta of 1.48. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. The stock's fifty day moving average is $12.73 and its 200 day moving average is $16.41. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $38.28.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical device company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.08). The company had revenue of $240.68 million for the quarter, compared to the consensus estimate of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The firm's revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the company earned ($0.47) EPS. Sell-side analysts anticipate that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, CEO John F. Sheridan bought 10,000 shares of the business's stock in a transaction on Monday, August 11th. The stock was bought at an average price of $10.23 per share, for a total transaction of $102,300.00. Following the completion of the transaction, the chief executive officer owned 106,327 shares in the company, valued at approximately $1,087,725.21. The trade was a 10.38% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Leigh Vosseller acquired 13,720 shares of the business's stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $10.89 per share, with a total value of $149,410.80. Following the transaction, the chief financial officer owned 25,580 shares of the company's stock, valued at approximately $278,566.20. The trade was a 115.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Tandem Diabetes Care

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sessa Capital IM L.P. acquired a new position in Tandem Diabetes Care during the first quarter worth approximately $85,574,000. GW&K Investment Management LLC grew its stake in Tandem Diabetes Care by 34.9% during the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company's stock worth $54,874,000 after buying an additional 740,499 shares during the period. Hood River Capital Management LLC grew its stake in Tandem Diabetes Care by 10.9% during the second quarter. Hood River Capital Management LLC now owns 2,564,978 shares of the medical device company's stock worth $47,811,000 after buying an additional 252,934 shares during the period. Paradice Investment Management LLC grew its stake in Tandem Diabetes Care by 24.3% during the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company's stock worth $26,665,000 after buying an additional 429,289 shares during the period. Finally, Stephens Investment Management Group LLC grew its stake in Tandem Diabetes Care by 1.8% during the second quarter. Stephens Investment Management Group LLC now owns 1,737,769 shares of the medical device company's stock worth $32,392,000 after buying an additional 30,854 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.